JP2012524771A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524771A5
JP2012524771A5 JP2012506583A JP2012506583A JP2012524771A5 JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5 JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5
Authority
JP
Japan
Prior art keywords
oil
eur
composition
composition according
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524771A (ja
Filing date
Publication date
Priority claimed from PCT/GB2009/050416 external-priority patent/WO2010122276A1/en
Priority claimed from GB0906977A external-priority patent/GB2469792A/en
Application filed filed Critical
Priority claimed from PCT/GB2010/050671 external-priority patent/WO2010122355A1/en
Publication of JP2012524771A publication Critical patent/JP2012524771A/ja
Publication of JP2012524771A5 publication Critical patent/JP2012524771A5/ja
Pending legal-status Critical Current

Links

JP2012506583A 2009-04-23 2010-04-23 中性油を含む舌下用の医薬組成物 Pending JP2012524771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2009/050416 WO2010122276A1 (en) 2009-04-23 2009-04-23 Drug delivery
GB0906977A GB2469792A (en) 2009-04-23 2009-04-23 Oil-based pharmaceutical formulation for sublingual delivery
GBPCT/GB2009/050416 2009-04-23
GB0906977.4 2009-04-23
PCT/GB2010/050671 WO2010122355A1 (en) 2009-04-23 2010-04-23 Sublingual pharmaceutical composition comprising a neutral oil

Publications (2)

Publication Number Publication Date
JP2012524771A JP2012524771A (ja) 2012-10-18
JP2012524771A5 true JP2012524771A5 (enExample) 2013-05-09

Family

ID=42236683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506583A Pending JP2012524771A (ja) 2009-04-23 2010-04-23 中性油を含む舌下用の医薬組成物

Country Status (15)

Country Link
US (1) US20120058158A1 (enExample)
EP (1) EP2421503A1 (enExample)
JP (1) JP2012524771A (enExample)
CN (1) CN102458358A (enExample)
AU (1) AU2010240653A1 (enExample)
BR (1) BRPI1013539A2 (enExample)
CA (1) CA2756879A1 (enExample)
IL (1) IL215454A (enExample)
MX (1) MX2011010835A (enExample)
MY (1) MY167918A (enExample)
NZ (1) NZ595467A (enExample)
RU (1) RU2011139638A (enExample)
SG (1) SG175160A1 (enExample)
WO (1) WO2010122355A1 (enExample)
ZA (1) ZA201107089B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US20130254139A1 (en) * 2012-03-21 2013-09-26 Xiaoguang Lei Systems and methods for building a universal intelligent assistant with learning capabilities
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10376586B2 (en) * 2016-02-16 2019-08-13 Entourage Bioscience, LLC Method and compositions for solubilizing non-polar constituents
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US11273131B2 (en) * 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
CA3048485C (en) * 2016-12-26 2022-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
CN111465391A (zh) * 2017-09-27 2020-07-28 阿奎斯蒂弗医疗股份有限公司 具有增强的递送的肾上腺素和前药的组合物
US12558305B2 (en) 2018-12-29 2026-02-24 Solventum Intellectual Properties Company Oral articles and methods of use
US12390488B2 (en) 2018-12-29 2025-08-19 Solventum Intellectual Properties Company Oral articles and methods of use
WO2021201680A1 (en) 2020-03-31 2021-10-07 Hasan Djohan Treatment of hyperinflammatory syndrome
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE71520T1 (de) * 1986-03-10 1992-02-15 Burghart Kurt Pharmazeutische zubereitung sowie verfahren zur herstellung derselben.
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
SI1976521T1 (sl) * 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
DK2424523T3 (da) * 2009-04-23 2012-09-24 Londonpharma Ltd Sublingual sprayformulering med dihydroartemisinin

Similar Documents

Publication Publication Date Title
RU2011139638A (ru) Сублингвальная фармацевтическая композиция, содержащая нейтральное масло
JP7250865B2 (ja) 固溶体組成物および心血管疾患における使用
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
JP2021107433A (ja) ω3脂肪酸の自己乳化組成物
RU2011148140A (ru) Самомикроэмульгирующаяся оральная фармацевтическая композиция, содержащая гидрофильное лекарственное средство, и способ ее приготовления
JP2015520235A5 (enExample)
JP2013508296A5 (enExample)
JP2014509655A5 (enExample)
JP2015520236A5 (enExample)
Aggarwal et al. Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation
RU2014139008A (ru) Гормонсодержащая эмульсия, содержащая фосфолипиды криля
WO2009139589A3 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
WO2002039983A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
RU2017111503A (ru) КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2015144013A (ru) Липидные композиции рацекадотрила
WO2008120711A1 (ja) タミバロテンカプセル剤
JP6521274B2 (ja) タキサンを含む経口投与用薬学的組成物
RU2015102597A (ru) Липидные композиции рацекадотрила
Goswami et al. Permeation enhancer for TDDS from natural and synthetic sources: A review
RU2013126259A (ru) Фармацевтическая композиция таксоидов
RU2017110076A (ru) Фармацевтическая композиция и способы
GB2469754A (en) Sub-lingual drug delivery system using a neutral oil
JP2022531685A5 (enExample)
HRP20151382T1 (hr) Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar
HRP20160446T1 (hr) Farmaceutski pripravci koji sadrže derivat kamptotecina